Literature DB >> 24456625

Yellow fever vaccine-associated adverse events following extensive immunization in Argentina.

Cristián Biscayart1, María Eugenia Pérez Carrega2, Sandra Sagradini2, Angela Gentile3, Daniel Stecher4, Tomás Orduna5, Silvia Bentancourt6, Salvador García Jiménez7, Luis Pedro Flynn8, Gabriel Pirán Arce9, María Andrea Uboldi10, Laura Bugna10, María Alejandra Morales11, Clara Digilio11, Cintia Fabbri11, Delia Enría11, Máximo Diosque2, Carla Vizzotti2.   

Abstract

As a consequence of YF outbreaks that hit Brazil, Argentina, and Paraguay in 2008-2009, a significant demand for YF vaccination was subsequently observed in Argentina, a country where the usual vaccine recommendations are restricted to provinces that border Brazil, Paraguay, and Bolivia. The goal of this paper is to describe the adverse events following immunization (AEFI) against YF in Argentina during the outbreak in the northeastern province of Misiones, which occurred from January 2008 to January 2009. During this time, a total of nine cases were reported, almost two million doses of vaccine were administered, and a total of 165 AEFI were reported from different provinces. Case study analyses were performed using two AEFI classifications. Forty-nine events were classified as related to the YF vaccine (24 serious and 1 fatal case), and 12 events were classified as inconclusive. As the use of the YF 17D vaccine can be a challenge to health systems of countries with different endemicity patterns, a careful clinical and epidemiological evaluation should be performed before its prescription to minimize serious adverse events.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Argentina; Safety; Severe adverse events; Yellow fever vaccine

Mesh:

Substances:

Year:  2014        PMID: 24456625     DOI: 10.1016/j.vaccine.2014.01.015

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Yellow fever vaccine-associated neurological disease: it is not just the silver generation at risk.

Authors:  Emily J Goldstein; David J Bell; Rory N Gunson
Journal:  BMJ Case Rep       Date:  2019-05-13

Review 2.  A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population.

Authors:  Ariane de Jesus Lopes de Abreu; João Roberto Cavalcante; Letícia Wigg de Araújo Lagos; Rosângela Caetano; José Ueleres Braga
Journal:  Vaccines (Basel)       Date:  2022-04-30

3.  The interferon signaling antagonist function of yellow fever virus NS5 protein is activated by type I interferon.

Authors:  Maudry Laurent-Rolle; Juliet Morrison; Ricardo Rajsbaum; Jesica M Levingston Macleod; Giuseppe Pisanelli; Alissa Pham; Juan Ayllon; Lisa Miorin; Carles Martinez; Benjamin R tenOever; Adolfo García-Sastre
Journal:  Cell Host Microbe       Date:  2014-09-10       Impact factor: 21.023

4.  Serious adverse events associated with yellow fever vaccine.

Authors:  Reinaldo de Menezes Martins; Maria da Luz Fernandes Leal; Akira Homma
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  Yellow fever vaccine-associated viscerotropic disease: current perspectives.

Authors:  Roger E Thomas
Journal:  Drug Des Devel Ther       Date:  2016-10-12       Impact factor: 4.162

6.  Safety of yellow fever vaccine in Indian travellers: A prospective observational study.

Authors:  Pramil Tiwari; Rajiv Ahlawat; Gaurav Gupta
Journal:  Indian J Med Res       Date:  2016-11       Impact factor: 2.375

Review 7.  Yellow fever in Africa and the Americas: a historical and epidemiological perspective.

Authors:  Jean-Philippe Chippaux; Alain Chippaux
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2018-08-25

Review 8.  Questions regarding the safety and duration of immunity following live yellow fever vaccination.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2016-06-20       Impact factor: 5.683

Review 9.  A clinician's perspective on yellow fever vaccine-associated neurotropic disease.

Authors:  Elien Lecomte; Guy Laureys; Frederick Verbeke; Cristina Domingo Carrasco; Marjan Van Esbroeck; Ralph Huits
Journal:  J Travel Med       Date:  2020-11-09       Impact factor: 8.490

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.